le mardi 16 octobre 2018, à 23:16. Posté
par Stuart
A law firm https://www.salesforceben.com/medicaremartinspointorg-4afb.pdf#computer medicare.martinspoint.org Patients with advanced breast cancer living in England and Wales will not be allowed routine access to Novartis' Afinitor on the National Health Service, following a decision from the National Institute for Health and Care Excellence that has angered the company and charities.